Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pain, Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Fractures, Bone

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Pain, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Bone Diseases, Metabolic, Breast Neoplasms

Breast Neoplasms, Multiple Myeloma

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

Breast Neoplasms, Fatigue

Breast Neoplasms

Breast Neoplasms, Carcinoma, Ductal, Breast

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Osteoporosis

Breast Neoplasms, Neovascularization, Pathologic

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Multiple Myeloma, Pain, Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Bone Diseases, Breast Neoplasms

Breast Neoplasms, Pain

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Breast Neoplasms

Bone Neoplasms, Breast Neoplasms, Multiple Myeloma, Prostatic Neoplasms, Renal Insufficiency

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Pain, Prostatic Neoplasms

Breast Neoplasms, Prostatic Neoplasms

Breast Neoplasms, Osteoporosis

Breast Neoplasms, Osteoporosis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplastic Cells, Circulating, Neoplasm Metastasis

Breast Neoplasms

Bone Diseases, Metabolic, Breast Neoplasms, Osteoporosis

Breast Neoplasms, Osteoporosis

Clinical Trials

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

REaCT-ZOL

Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

ANZAC

Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

HOBOE

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole

Study on Bisphosphonates Targeting Triple-negative Breast Cancer

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

BLAZE

Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year

REaCT-BTA

PBCB

Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

NEO-ZOTAC

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NEOZOL

Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Pre-operative Zoledronate in Triple Negative Breast Cancer

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)

ER11-03

ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy

Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases

Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases

Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer

Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer

Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer

The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

NATAN

A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

MACS1295

CTIBL

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer